- Home
- PETZ vs KZIA Comparison
PETZ vs KZIA Comparison
Compare PETZ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- KZIA
- Stock Information
- Founded
- PETZ 2002
- KZIA 1994
- Country
- PETZ China
- KZIA Australia
- Employees
- PETZ N/A
- KZIA N/A
- Industry
- PETZ Steel/Iron Ore
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- KZIA Health Care
- Exchange
- PETZ Nasdaq
- KZIA Nasdaq
- Market Cap
- PETZ 9.3M
- KZIA 9.0M
- IPO Year
- PETZ 2017
- KZIA 1999
- Fundamental
- Price
- PETZ $1.03
- KZIA $8.05
- Analyst Decision
- PETZ
- KZIA Strong Buy
- Analyst Count
- PETZ 0
- KZIA 2
- Target Price
- PETZ N/A
- KZIA $14.00
- AVG Volume (30 Days)
- PETZ 5.3K
- KZIA 18.7K
- Earning Date
- PETZ 04-28-2025
- KZIA 06-05-2025
- Dividend Yield
- PETZ N/A
- KZIA N/A
- EPS Growth
- PETZ N/A
- KZIA N/A
- EPS
- PETZ 0.26
- KZIA N/A
- Revenue
- PETZ $563,726.00
- KZIA $1,549,158.00
- Revenue This Year
- PETZ N/A
- KZIA N/A
- Revenue Next Year
- PETZ N/A
- KZIA $49.25
- P/E Ratio
- PETZ $5.08
- KZIA N/A
- Revenue Growth
- PETZ 74664.72
- KZIA 248983.08
- 52 Week Low
- PETZ $0.65
- KZIA $2.86
- 52 Week High
- PETZ $1.74
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- PETZ 52.58
- KZIA 50.39
- Support Level
- PETZ $1.02
- KZIA $7.52
- Resistance Level
- PETZ $1.10
- KZIA $8.39
- Average True Range (ATR)
- PETZ 0.04
- KZIA 0.66
- MACD
- PETZ 0.00
- KZIA 0.05
- Stochastic Oscillator
- PETZ 39.83
- KZIA 68.28
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.